Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCP2 | P22307 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 10/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812016 | 0.88 | SCP2 (0.78) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL14267417 | 0.87 | SCP2 (1.00) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL7815701 | 0.86 | SCP2 (0.79) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL4662802 | 0.86 | SCP2 (0.56) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL7812704 | 0.84 | SCP2 (0.93) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL62370 | 0.82 | SCP2 (0.77) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL19646592 | 0.81 | SCP2 (0.77) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL7805770 | 0.81 | SCP2 (0.65) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL26434823 | 0.81 | SCP2 (0.76) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL3501312 | 0.81 | SCP2 (0.82) | SCP2MEN1NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080038840-A1 | Fluorescent Method And Compounds To Monitor Protein-Lipid Binding | EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1747207-A1 | FLUORESCENT METHOD AND COMPOUNDS TO MONITOR PROTEIN-LIPID BINDING | EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005113524-A1 | FLUORESCENT METHOD AND COMPOUNDS TO MONITOR PROTEIN-LIPID BINDING | Europäisches Laboratorium für Molekularbiologie (EMBL) (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038840-A1 | Fluorescent Method And Compounds To Monitor Protein-Lipid Binding | DBI, CETP, SREBF1 | SCP2 34/4885MEN1 3143/4885NPC1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.